Pan Bo, Yao Ru, Shi Jie, Xu Qian-Qian, Zhou Yi-Dong, Mao Feng, Lin Yan, Guan Jing-Hong, Wang Xue-Jing, Zhang Yan-Na, Zhang Xiao-Hui, Shen Song-Jie, Zhong Ying, Xu Ya-Li, Zhu Qing-Li, Liang Zhi-Yong, Sun Qiang
Department of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.
Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.
Oncotarget. 2016 Jun 21;7(25):38864-38875. doi: 10.18632/oncotarget.8778.
The heterogeneous nature of the mucinous breast cancer (MBC), with its pure (PMBC) and mixed subtypes (MMBC), calls for precise prognosis assessment.
We analyzed 197 consecutive MBC patients, including 117 PMBC and 80 MMBC, who were treated from 1983 to 2014. The clinicopathological features, treatment choice, disease-free survival (DFS) and overall survival (OS) were compared among PMBC, MMBC and MMBC subgroups. Prognostic factors of PMBC and MMBC were identified.
Compared to PMBC, MMBC had more lymph node metastasis (p = 0.043), Her2 positivity (p = 0.036), high Ki-67 index (defined as>20%, p = 0.026) and anti-Her2 targeted therapy (p = 0.016). The 5-year DFS of PMBC and MMBC were 90.4% and 86.2%, whereas the 5-year OS were 99.0% and 98.7%. No significant difference was found in DFS or OS among all MBC subtypes. High Ki-67 (p = 0.020) appeared as DFS factor in PMBC, while anti-Her2 targeted therapy (p = 0.047) as the DFS predictors in MMBC.
MMBC manifested similar 5-year survival to PMBC in Chinese woman, suggesting that intra-tumoral heterogeneity might not interfere with MBC short-term prognosis.
黏液性乳腺癌（MBC）具有异质性，包括纯黏液性乳腺癌（PMBC）和混合亚型（MMBC），需要进行精确的预后评估。
我们分析了197例连续的MBC患者，其中包括117例PMBC和80例MMBC，这些患者于1983年至2014年接受治疗。比较了PMBC、MMBC和MMBC亚组的临床病理特征、治疗选择、无病生存期（DFS）和总生存期（OS）。确定了PMBC和MMBC的预后因素。
与PMBC相比，MMBC有更多的淋巴结转移（p = 0.043）、Her2阳性（p = 0.036）、高Ki-67指数（定义为>20%，p = 0.026）和抗Her2靶向治疗（p = 0.016）。PMBC和MMBC的5年DFS分别为90.4%和86.2%，而5年OS分别为99.0%和98.7%。所有MBC亚型的DFS或OS均未发现显著差异。高Ki-67（p = 0.020）在PMBC中表现为DFS因素，而抗Her2靶向治疗（p = 0.047）在MMBC中为DFS预测因素。
在中国女性中，MMBC的5年生存率与PMBC相似，这表明肿瘤内异质性可能不会干扰MBC的短期预后。
